{
    "ticker": "GNFT",
    "name": "Genfit SA",
    "description": "Genfit SA is a biopharmaceutical company focused on discovering and developing innovative therapeutic and diagnostic solutions for liver diseases, particularly non-alcoholic steatohepatitis (NASH) and other metabolic disorders. Founded in 2008 and headquartered in Lille, France, Genfit is at the forefront of addressing the growing global health challenge posed by liver diseases, which are often linked to obesity, diabetes, and metabolic syndrome. The company\u2019s lead product candidate, Elafibranor, is designed to target the underlying mechanisms of NASH and has shown promising results in clinical trials. Genfit is also advancing its pipeline of biomarkers aimed at enhancing the diagnosis and treatment of liver diseases. The company is committed to leveraging cutting-edge science and technology to create meaningful advancements in patient care. With a robust R&D program and a team of dedicated professionals, Genfit is positioned to be a leader in the field of liver health, striving to improve the lives of patients worldwide through innovative therapies and diagnostics.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Lille, France",
    "founded": "2008",
    "website": "https://www.genfit.com",
    "ceo": "Jean-Fran\u00e7ois Mouney",
    "social_media": {
        "twitter": "https://twitter.com/genfit",
        "linkedin": "https://www.linkedin.com/company/genfit/"
    },
    "investor_relations": "https://www.genfit.com/en/investors/",
    "key_executives": [
        {
            "name": "Jean-Fran\u00e7ois Mouney",
            "position": "CEO"
        },
        {
            "name": "Alain Dufour",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Elafibranor"
            ]
        },
        {
            "category": "Diagnostics",
            "products": [
                "NASH biomarkers"
            ]
        }
    ],
    "seo": {
        "meta_title": "Genfit SA | Innovating Liver Disease Therapies and Diagnostics",
        "meta_description": "Genfit SA is a biopharmaceutical company focused on innovative therapies for liver diseases, including NASH. Explore our research, products, and commitment to patient care.",
        "keywords": [
            "Genfit",
            "Liver Disease",
            "NASH",
            "Biotechnology",
            "Pharmaceuticals",
            "Elafibranor"
        ]
    },
    "faq": [
        {
            "question": "What is Genfit known for?",
            "answer": "Genfit is known for its innovative therapies and diagnostics for liver diseases, particularly non-alcoholic steatohepatitis (NASH)."
        },
        {
            "question": "Who is the CEO of Genfit?",
            "answer": "Jean-Fran\u00e7ois Mouney is the CEO of Genfit SA."
        },
        {
            "question": "Where is Genfit headquartered?",
            "answer": "Genfit is headquartered in Lille, France."
        },
        {
            "question": "What are Genfit's main products?",
            "answer": "Genfit's main product is Elafibranor, aimed at treating NASH, along with various biomarkers for liver disease diagnosis."
        },
        {
            "question": "When was Genfit founded?",
            "answer": "Genfit was founded in 2008."
        }
    ],
    "competitors": [
        "MRNA",
        "AMGN",
        "REGN"
    ],
    "related_stocks": [
        "AAPL",
        "GOOGL",
        "AMZN",
        "MSFT"
    ]
}